Supplementary Table 1 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma od Duygu Kuzuoglu-Ozturk (14960213)

Teme:

Supplementary Table 2 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma od Duygu Kuzuoglu-Ozturk (14960213)

Teme:

Supplementary Table 3 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma od Duygu Kuzuoglu-Ozturk (14960213)

Teme:

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models od Katie E. Hebron (15046889)

Teme:

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models od Katie E. Hebron (15046889)

Teme:

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models od Katie E. Hebron (15046889)

Teme:

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models od Katie E. Hebron (15046889)

Teme:

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models od Katie E. Hebron (15046889)

Teme:

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models od Katie E. Hebron (15046889)

Teme:

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models od Katie E. Hebron (15046889)

Teme:

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models od Elizabeth R. Tucker (15053624)

Teme:

Figure 4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses od Ernesto Gargiulo (15134961)

Teme:

Supplementary Table S4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses od Ernesto Gargiulo (15134961)

Teme:

Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses od Ernesto Gargiulo (15134961)

Teme:

Figure 1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses od Ernesto Gargiulo (15134961)

Teme:

Figure 7 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses od Ernesto Gargiulo (15134961)

Teme:

Figure 5 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses od Ernesto Gargiulo (15134961)

Teme:

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models od Elizabeth R. Tucker (15053624)

Teme:

Figure 3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses od Ernesto Gargiulo (15134961)

Teme:

Supplementary Table S1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses od Ernesto Gargiulo (15134961)

Teme: